secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001140361-26-006981
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma FY2025 net loss $223.1M; cash $188.9M; KRESLADI PDUFA March 28, 2026
--------------------------------------------------------------------------------

- Net loss $223.1M ($2.01/shr) vs $258.7M ($2.73/shr) in FY2024; R&D spend down 17% to $142.0M.
- Cash, cash equivalents & investments $188.9M; runway into Q2 2027; restructuring charges $3.2M.
- Pivotal Phase 2 trial of RP-A501 (Danon disease) to resume 1H 2026 after FDA lifted clinical hold.
- KRESLADI BLA resubmission accepted; PDUFA target action date March 28, 2026; eligible for PRV.
- First patient dosing in Phase 1 RP-A701 (BAG3-DCM) expected mid-2026; Phase 1 trial startup ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/0001140361-26-006981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-006981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer